Erytech Pharma (NASDAQ:ERYP) – Research analysts at Jefferies Group lowered their FY2018 earnings estimates for shares of Erytech Pharma in a report released on Tuesday, March 13th, Zacks Investment Research reports. Jefferies Group analyst P. Welford now anticipates that the company will post earnings of ($2.50) per share for the year, down from their prior estimate of ($1.99). Jefferies Group also issued estimates for Erytech Pharma’s FY2019 earnings at ($2.82) EPS, FY2020 earnings at ($3.43) EPS and FY2021 earnings at ($3.57) EPS.
ERYP traded down $0.12 during trading on Friday, hitting $20.44. The company had a trading volume of 1,100 shares, compared to its average volume of 495. The stock has a market capitalization of $366.63 and a P/E ratio of -6.72. Erytech Pharma has a one year low of $17.50 and a one year high of $30.56.
A number of institutional investors and hedge funds have recently bought and sold shares of ERYP. BVF Inc. IL bought a new stake in Erytech Pharma in the 4th quarter valued at $13,763,000. Sphera Funds Management LTD. bought a new stake in Erytech Pharma in the 4th quarter valued at $2,642,000. Delek Group Ltd. bought a new stake in Erytech Pharma in the 4th quarter valued at $1,539,000. Millennium Management LLC bought a new stake in Erytech Pharma in the 4th quarter valued at $959,000. Finally, Jane Street Group LLC bought a new stake in Erytech Pharma in the 4th quarter valued at $607,000. 26.91% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Brokers Set Expectations for Erytech Pharma’s FY2018 Earnings (NASDAQ:ERYP)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/jefferies-group-weighs-in-on-erytech-pharma-sas-fy2018-earnings-eryp.html.
Erytech Pharma Company Profile
Get a free copy of the Zacks research report on Erytech Pharma (ERYP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.